This is a StreetInsider.com Premium Only Page

Aimmune Therapeutics (AIMT) – StreetInsider.com Reports

Sep 14, 2020 06:09 AM Aimmune Therapeutics (AIMT) Receives $34.50/Sh Cash Tender Offer from Nestle

Sep 1, 2020 06:45 AM Aimmune Therapeutics (AIMT) PT Lowered to $35 at Baird

Aug 31, 2020 10:13 PM Cantor Fitzgerald Downgrades Aimmune Therapeutics (AIMT) to Neutral

Aug 31, 2020 04:17 PM Aimmune Therapeutics (AIMT) PT Raised to $34.50 at Credit Suisse

Aug 31, 2020 04:09 PM Wedbush Downgrades Aimmune Therapeutics (AIMT) to Neutral

Aug 31, 2020 09:35 AM Increasing unusual option volume: AIMT JAMF PEIX BCS

Aug 31, 2020 09:19 AM Piper Sandler Downgrades Aimmune Therapeutics (AIMT) to Neutral

Aug 31, 2020 08:53 AM Pre-Open Stock Movers 8/31: (AIMT) (AKCA) (GNW) (ACST) (LPCN) (BIGC) (More...)

Aug 31, 2020 06:04 AM Aimmune Therapeutics (AIMT) Confirms $2B Acquisition by Nestle at $34.50/Sh

Aug 31, 2020 01:31 AM Nestle gets peanut allergy treatment with $2 billion Aimmune buyout

Jul 31, 2020 01:44 PM Aimmune Therapeutics (AIMT) PT Lowered to $14 at Credit Suisse, Following Earnings

Jul 31, 2020 08:18 AM Aimmune Therapeutics (AIMT) PT Lowered to $40 at RBC Capital

Jul 30, 2020 04:56 PM Aimmune Therapeutics (AIMT) Tops Q2 EPS by 3c

Jul 23, 2020 07:26 AM UPDATE: Aimmune Therapeutics (AIMT) PT Cut to $18 at Stifel After Poor Responses in Allergist Survey

Jul 21, 2020 08:32 AM Aimmune Therapeutics (AIMT) Announces Full Results of its Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA Published in The Lancet Child & Adolescent Health

Jul 13, 2020 05:49 AM Cowen Starts Aimmune Therapeutics (AIMT) at Outperform

Jun 26, 2020 07:25 AM Companies with NDRs 6/26

Jun 25, 2020 07:51 AM Companies with NDRs 6/25

Jun 23, 2020 06:50 AM Companies with NDRs 6/23

Jun 22, 2020 07:06 AM Companies with NDRs 6/22

Jun 8, 2020 08:05 AM Aimmune Therapeutics (AIMT) Reports New Data from Ph. 3 ARTEMIS Trial Showing Patients are Confident in Efficacy of Daily Treatment w/ PALFORZIA after 9-Mo

May 12, 2020 06:13 AM Aimmune Therapeutics (AIMT) PT Lowered to $52 at RBC Capital

May 12, 2020 04:36 AM Aimmune Therapeutics (AIMT) PT Lowered to $20 at Stifel

May 11, 2020 04:08 PM Aimmune Therapeutics (AIMT) Tops Q1 EPS by 15c

Apr 30, 2020 12:17 PM Aimmune Therapeutics (AIMT) Ticks Higher on Chatter

Mar 18, 2020 04:00 AM JMP Securities Downgrades Aimmune Therapeutics (AIMT) to Market Perform

Mar 12, 2020 06:37 AM Aimmune Therapeutics (AIMT) PT Lowered to $22 at Goldman Sachs

Mar 3, 2020 04:50 PM Aimmune Therapeutics (AIMT) PT Lowered to $66 at Wedbush

Mar 2, 2020 06:10 AM Aimmune Therapeutics (AIMT) PT Lowered to $29 at Credit Suisse

Mar 1, 2020 05:22 PM Aimmune Therapeutics (AIMT) PT Lowered to $32 at Stifel

Feb 27, 2020 04:24 PM Aimmune Therapeutics (AIMT) Reports In-Line Q4 EPS

Feb 5, 2020 01:15 PM Aimmune Therapeutics (AIMT) PT Lowered to $74 at Wedbush, Maintains 'Outperform'

Feb 5, 2020 09:15 AM Pre-Open Stock Movers 2/5: (ABUS) (COTY) (QGEN) Higher (PLT) (KN) (SNAP) Lower (more...)

Feb 5, 2020 08:58 AM Nestle Invest Another $200M in Aimmune Therapeutics (AIMT)

Feb 5, 2020 08:08 AM Aimmune Therapeutics (AIMT) Reports Licensing of Exclusive Worldwide Rights to Xencor (XNCR) XmAb7195 for Development of Next-Generation Food Allergy Treatments

Feb 4, 2020 05:47 AM Aimmune Therapeutics (AIMT) PT Raised to $34 at Credit Suisse

Feb 3, 2020 12:53 PM Aimmune Therapeutics (AIMT) PT Raised to $81 at Wedbush

Feb 3, 2020 09:23 AM Pre-Open Movers 02/03: (INSM) (AIMT) (GILD) Higher; (NKTR) (CHKP) (NOC) Lower (more...)

Feb 3, 2020 07:03 AM Aimmune Therapeutics (AIMT) PT Raised to $70 at Stifel

Feb 3, 2020 06:58 AM Aimmune Therapeutics (AIMT) Confirms FDA Approves its PALFORZIA as First Treatment for Peanut Allergy

Feb 3, 2020 04:40 AM Aimmune Therapeutics (AIMT) PT Raised to $44 at JMP Securities

Dec 19, 2019 07:11 AM H.C. Wainwright Starts Aimmune Therapeutics (AIMT) at Neutral

Dec 13, 2019 04:55 AM Credit Suisse Downgrades Aimmune Therapeutics (AIMT) to Neutral

Nov 8, 2019 07:16 AM Aimmune Therapeutics (AIMT) Reports AR101 Demonstrates Consistent Efficacy & Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data

Nov 6, 2019 05:10 PM Aimmune Therapeutics (AIMT) Reports In-Line Q3 EPS

Oct 25, 2019 05:55 AM Aimmune Therapeutics (AIMT) PT Raised to $27 at Goldman Sachs

Oct 25, 2019 05:13 AM Increasing unusual option volume: ATVI AIMT CRON CYH NPTN WVE PRO FTV DXJ

Oct 24, 2019 01:58 PM Call Buying Activity in Aimmune Therapeutics (AIMT) Highlights 'Speculative Bullish' Sentiment in Shares Through December -Susquehanna

Oct 24, 2019 12:45 PM Aimmune Therapeutics (AIMT) call put ratio 88 calls to 1 put with focus on December 30 calls

Oct 24, 2019 07:14 AM Aimmune Therapeutics (AIMT) PT Raised to $27 at Goldman Sachs